# A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)

> **NCT01165320** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 20 (actual)

## Conditions studied

- Candidiasis, Esophageal
- Candidiasis, Invasive
- Aspergillosis

## Interventions

- **DRUG:** Caspofungin

## Key facts

- **NCT ID:** NCT01165320
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07-06
- **Primary completion:** 2013-09-17
- **Final completion:** 2013-09-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2018-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01165320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01165320, "A Study of Caspofungin (MK-0991) in Japanese Children and Adolescents With Documented Candida or Aspergillus Infections (MK-0991-074)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01165320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*